JBIO

← Markets

JBIOJade Biosciences, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Tue, Jun 30
8:21 AMYahooIs Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Fri, Jun 26
6:00 AMYahooJade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Fri, Jun 5
3:01 PMYahooJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Wed, Jun 3
9:58 PMYahooJade Biosciences Announces Pricing of Public Offering of Common Stock
3:01 PMYahooJade Biosciences Announces Proposed Underwritten Public Offering
Mon, Jun 1
8:07 PMmarketbeat.comJade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
6:00 AMYahooJade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Fri, May 29
3:05 PMYahooJade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
Thu, May 28
8:03 PMYahooAssessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains
Tue, May 26
3:05 PMYahooJade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
6:00 AMYahooJade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Thu, May 7
3:05 PMYahooJade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update